Free Hematology CME

Patient advocate and HealthTree Foundation CEO Jenny Ahlstrom shares fresh survey insights into the physical, emotional, and social quality-of-life experiences of patients treated with bispecific antibodies, while spotlighting key educational, financial, and community resources designed to support them.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Discover how communities of practice are expanding access to bispecific antibodies, as faculty share practical guidance on starting these therapies in community settings and smoothly transitioning patients from academic centers to local care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Faculty discusses the prevention and management of cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and infections in patients with relapsed/refractory multiple myeloma treated with BCMA-directed bispecific antibodies.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Expert faculty dive into the rapidly evolving world of BCMA-directed bispecific antibodies for multiple myeloma, exploring practical strategies to bring these cutting-edge therapies into everyday clinical care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Empowering the Care Team: Practical Strategies for Implementing BCMA Therapies in Relapsed Refractory Multiple Myeloma

Through interactive cases and expert-led discussions, our ECHO® sessions and Community of Practice calls help community oncology teams:

• Characterize the safety and efficacy of BCMA-directed bsAbs for the treatment of MM
• Appropriately incorporate BCMA-directed bsAbs into cases of patients with MM that are representative of clinical practice
• Establish and follow workflows and lines of communication for monitoring and managing BCMA bsAb treatment-related adverse events
• Summarize the importance and benefits of CoPs to providing coordinated, multidisciplinary, and interprofessional care for patients with MM receiving BCMA-directed bsAbs